We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BMS-Celgene

News List

Questions about BMS-Celgene integration plans? Obviously. Answers? Not so much fiercepharma
April 29, 2019
Now that shareholders have voted for the deal, Bristol-Myers Squibb faces some serious pressure to prove its Celgene buyout will actually pay off. So it's no wonder analysts are demanding to know...
BMS-Celgene merger chances improve with backing from proxy advisers fiercepharma
April 02, 2019
When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up.
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss fiercepharma
January 08, 2019
Executives from Bristol-Myers Squibb and Celgene were just a few minutes into a Q&A with investors about their newly announced $74 billion merger when longtime biotech analyst Tim Anderson raised a troubling question.